EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial. Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Biomarkers, Tumor
  • Breast Neoplasms
  • Receptor, Epidermal Growth Factor

abstract

  • High expression of EGFR appears to be associated with decreased benefit from adjuvant concurrent trastuzumab. Since other treatment options exist for HER2-driven tumours, further validation of these data may select patients for alternative or additive therapy.

publication date

  • January 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4453859

Digital Object Identifier (DOI)

  • 10.1038/bjc.2014.442

PubMed ID

  • 25117817

Additional Document Info

start page

  • 1065

end page

  • 71

volume

  • 111

number

  • 6